Evidence map›Paper›PMID 39092332›Full record

ReviewCureus2024

Emerging Treatments and Therapies for Autism Spectrum Disorder: A Narrative Review.

Alan D Kaye, Kaitlyn E Allen, Van S Smith Iii, Victoria T Tong, Vivian E Mire, Huy Nguyen, Zachary Lee, Maria Kouri, Carlo Jean Baptiste, Chizoba N Mosieri and 3 more

Abstract readReview
In one paragraph

Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alan D KayeDepartment of Anesthesiology, Louisiana State University Health Sciences Center, Shreveport, USA.
Kaitlyn E AllenSchool of Medicine, Louisiana State University Health New Orleans School of Medicine, New Orleans, USA.
Van S Smith IiiSchool of Medicine, Louisiana State University Health Sciences Center, Shreveport, USA.
Victoria T TongSchool of Medicine, Louisiana State University Health New Orleans School of Medicine, New Orleans, USA.
Vivian E MireSchool of Medicine, Louisiana State University Health New Orleans School of Medicine, New Orleans, USA.
Huy NguyenSchool of Medicine, Louisiana State University Health Sciences Center, Shreveport, USA.
Zachary LeeSchool of Medicine, Louisiana State University Health Sciences Center, Shreveport, USA.
Maria KouriAnesthesia, National and Kapodistrian University of Athens, Athens, GRC.
Carlo Jean BaptisteDepartment of Anesthesiology, Louisiana State University Health Sciences Center, Shreveport, USA.
Chizoba N MosieriDepartment of Anesthesiology, Louisiana State University Health Sciences Center, Shreveport, USA.
Adam M KayeDepartment of Pharmacy Practice, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, USA.
Giustino VarrassiPain Medicine, Paolo Procacci Foundation, Rome, ITA.
Sahar ShekoohiDepartment of Anesthesiology, Louisiana State University Health Sciences Center, Shreveport, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prevalence of autism spectrum disorder (ASD) has increased over the last decade. In this regard, many emerging therapies have been described as ASD therapies. Although ASD does not have a cure, there are several management options available that can help reduce symptom severity. ASD is highly variable and, therefore, standard treatment protocols and studies are challenging to perform. Many of these therapies also address comorbidities for which patients with ASD have an increased risk. These concurrent diagnoses can include psychiatric and neurological disorders, including attention deficit and hyperactivity disorder, anxiety disorders, and epilepsy, as well as gastrointestinal symptoms such as chronic constipation and diarrhea. Both the extensive list of ASD-associated disorders and adverse effects from commonly prescribed medications for patients with ASD can impact presenting symptomatology. It is important to keep these potential interactions in mind when considering additional drug treatments or complementary therapies. This review addresses current literature involving novel pharmacological treatments such as oxytocin, bumetanide, acetylcholinesterase inhibitors, and memantine. It also discusses additional therapies such as diet intervention, acupuncture, music therapy, melatonin, and the use of technology to aid education. Notably, several of these therapies require more long-term research to determine efficacy in specific ASD groups within this patient population.

Indexed as

autism spectrum disordercomorbiditiescomplementarymusic therapyoxytocin

Identifiers

PMID39092332
PMCPMC11293483

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.